scholarly journals Radiological Red Flags of Triple Negative Breast Cancer on Mammography and Ultrasonography: A Case-control Study

Author(s):  
Anjum Syed ◽  
Manali Arora ◽  
Vimugdha Premi ◽  
Prateek Sharda ◽  
Reshma Varghese ◽  
...  

Introduction: Breast cancer is the most common cause of cancer related mortality in Indian women. Aim: To evaluate the imaging characters of Triple Negative Breast Cancer (TNBC) on Mammography and Ultrasonography (USG), with the major goal of identifying imaging predictors of TNBC. Materials and Methods: The present retrospective case-control study was conducted at AIIMS, Rishikesh, Uttarakhand, India, over a period of one year from September 2018 to August 2019. The imaging findings of 50 cases of histopathologically proven TNBC were retrospectively evaluated by two breast radiologists. This was compared with 50 age matched blindly chosen cases of non-TNBC. The statistically significant imaging characters of TNBC were identified by Chi-square test. The imaging predictors of TNBC were identified by regression analysis. Results: The most common mammographic presentation of TNBC was mass without calcification (64%) with round/oval shape (54%) and lobulated margins (38%). The most common ultrasonographic presentation was hypoechoic mass (76%) with round/oval shape (52%) and lobulated margins (44%) with Posterior Acoustic Enhancement (PAE) (54%). PAE (p<0.0001: Area Under Curve (AUC): 0.6200) on USG was the single strongest imaging predictor of TNBC, followed by lobulated margins on mammography (p<0.001: AUC: 0.6300). On multivariate analysis, a lobulated, hypoechoic mass with PAE was found to be the most statistically confident predictor of TNBC on imaging. Conclusion: TNBC has specific imaging features on both mammography and USG which may be used as utility tools in early diagnosis. A round, lobulated mass on both modalities with hypoechogenicity and PAE on USG are definite red flags for TNBC on imaging.

Oncotarget ◽  
2018 ◽  
Vol 9 (97) ◽  
pp. 36906-36913 ◽  
Author(s):  
Despoina Kalapanida ◽  
Flora Zagouri ◽  
Maria Gazouli ◽  
Eleni Zografos ◽  
Constantine Dimitrakakis ◽  
...  

2019 ◽  
Vol Volume 12 ◽  
pp. 4195-4202
Author(s):  
Despoina Kalapanida ◽  
Flora Zagouri ◽  
Maria Gazouli ◽  
Andriani Tsiakou ◽  
Eleni Zografos ◽  
...  

2018 ◽  
Vol 18 (5) ◽  
pp. e773-e780 ◽  
Author(s):  
Icro Meattini ◽  
Donato Pezzulla ◽  
Calogero Saieva ◽  
Marco Bernini ◽  
Lorenzo Orzalesi ◽  
...  

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18579-e18579
Author(s):  
Joanna Zurko ◽  
Aniko Szabo ◽  
Yee Chung Cheng ◽  
Sailaja Kamaraju ◽  
John Burfeind ◽  
...  

e18579 Background: Patients with cancer have increased risk of developing SARS-Cov-2 (COVID-19) infection. It is unknown if characteristics related to breast cancer increase the risk of COVID-19 infection. In this retrospective matched case control study, we aim to identify breast cancer related risk factors associated with developing COVID-19 and describe outcomes of patients with breast cancer diagnosed with COVID-19. Methods: Women with breast cancer treated at the Medical College of Wisconsin and diagnosed with COVID-19 between March and December 2020 served as cases. Women with breast cancer without COVID-19 diagnosis within the same time frame were identified as potential controls. Controls were chosen by matching for age (≥60 vs <60), obesity (BMI <30 vs ≥30), county (Milwaukee vs suburban), race (white vs non-white) and diabetes mellitus (DM) with 3:1 matching planned. Univariate comparisons between cases and controls were done via Rao-Scott stratified chi-square test for categorical outcomes and stratified t-test for continuous variables. Conditional logistic regression was done to evaluate the joint effect of multiple characteristics on the odds of being a COVID-19 case. Results: Twenty-five cases and 77 controls were identified. All cases were fully matched by age, obesity, county, and race with 3 cases not able to be matched for DM. Mean age was 54.6 vs 54.9 (p=0.88), BMI 31.0 vs 31.6 (p=0.69), 48% lived in Milwaukee county and 68% were white (cases 24% black & 8% American Indian; controls 32% black). Regarding COVID outcomes, 24.0% (n=6) of cases were hospitalized, median length of stay was 2 days, 8% (n=2) needed oxygen, 4% (n=1) were intubated and 4% (n=1) died due to COVID-19. COVID-19 led to treatment delays in 40% of cases. On univariate analysis of cases vs controls, 64 vs 75% were ER/PR+ (p=0.31), 6.5 vs 5.2% HER2+ (p=0.34), and 9.0 vs 4.2% triple negative (p=0.10). There were no significant differences in breast cancer stage. At time of COVID diagnosis (or last clinic contact if control), 16 vs 14% had active disease (p=0.81), 72 vs 74% were on active treatment (p=0.85), with 21 vs 4% being on chemotherapy (p=0.007), and 44 vs 52% on endocrine therapy (p=0.49). On conditional logistic regression, being on active chemotherapy (OR 5.8, p=0.043) significantly increased the likelihood of developing COVID with a trend seen for triple negative disease (OR 2.8, p=0.12). Conclusions: In this matched case control study of patients with breast cancer, active chemotherapy was significantly associated with an increased likelihood of developing COVID-19 with a trend seen for triple negative disease. Rates of death due to COVID-19 were overall low. Our analysis was limited by small numbers and an inability to fully match patients for DM. These findings support continued strict precautions for those on active chemotherapy and warrants further analysis in those with triple negative disease.


2019 ◽  
Author(s):  
Jonine Figueroa ◽  
Brittny C. Davis Lynn ◽  
Lawrence Edusei ◽  
Nicholas Titiloye ◽  
Ernest Adjei ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document